FLAM
First Light Asset Management Portfolio holdings
AUM
$771M
This Quarter Return
-12.67%
1 Year Return
+33.17%
3 Year Return
+208.13%
5 Year Return
+426.73%
10 Year Return
+3,318.8%
AUM
$586M
AUM Growth
+$586M
(-25%)
Cap. Flow
-$69.1M
Cap. Flow
% of AUM
-11.8%
Top 10 Holdings %
Top 10 Hldgs %
50.11%
Holding
80
New
11
Increased
14
Reduced
24
Closed
16
Top Buys
| 1 |
CareDx
CDNA
|
$23.7M |
| 2 |
SPNE
SeaSpine Holdings Corporation Common Stock
SPNE
|
$21.8M |
| 3 |
PFNX
Pfenex Inc.
PFNX
|
$20.6M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$15.9M |
| 5 |
United Therapeutics
UTHR
|
$12.2M |
Top Sells
| 1 |
Omnicell
OMCL
|
$37.1M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$24.1M |
| 3 |
MODN
MODEL N, INC.
MODN
|
$23M |
| 4 |
NeoGenomics
NEO
|
$20.1M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$19.3M |
Sector Composition
| 1 | Healthcare | 77.23% |
| 2 | Communication Services | 3.51% |
| 3 | Industrials | 1.19% |
| 4 | Energy | 0.34% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DYNT
51
DELISTED
Dynatronics Corp
DYNT
| $389K | 0.07% |
450,000
+323,956
| +257% | +$280K |
|
|
AGN
52
DELISTED
Allergan plc
AGN
| $382K | 0.07% |
2,157
| – | – |
|
53
Merck
MRK
$210B
| $327K | 0.06% |
4,247
| – | – |
|
54
AbbVie
ABBV
$374B
| $313K | 0.05% |
4,114
| – | – |
|
55
Novartis
NVS
$248B
| $291K | 0.05% |
3,535
| – | – |
|
56
Sanofi
SNY
$122B
| $291K | 0.05% |
6,650
| – | – |
|
57
Health Catalyst
HCAT
$228M
| $290K | 0.05% |
11,100
| – | – |
|
58
Johnson & Johnson
JNJ
$429B
| $283K | 0.05% |
2,161
| – | – |
|
59
Pfizer
PFE
$141B
| $276K | 0.05% |
8,469
| – | – |
|
60
Baxter International
BAX
$12.1B
| $265K | 0.05% |
3,258
| – | – |
|
61
Amgen
AMGN
$153B
| $221K | 0.04% |
1,092
| – | – |
|
62
Direxion Daily S&P Biotech Bear 3X Shares
LABD
$60.3M
| $217K | 0.04% |
+15,401
| New | +$217K |
|
|
HRC
63
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $213K | 0.04% |
2,121
| – | – |
|
64
Grifois
GRFS
$6.53B
| $205K | 0.04% |
10,166
| – | – |
|
65
Agilent Technologies
A
$35.5B
| – | – |
-2,548
| Closed | -$217K |
|
66
Bio-Rad Laboratories Class A
BIO
$7.8B
| – | – |
-548
| Closed | -$203K |
|
67
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
-10,200
| Closed | -$655K |
|
68
Elevance Health
ELV
$72.4B
| – | – |
-795
| Closed | -$240K |
|
|
69
Omnicell
OMCL
$1.51B
| – | – |
-453,504
| Closed | -$37.1M |
|
70
Smith & Nephew
SNN
$16.2B
| – | – |
-4,472
| Closed | -$215K |
|
71
Steris
STE
$23.9B
| – | – |
-1,649
| Closed | -$251K |
|
72
Transmedics
TMDX
$3.65B
| – | – |
-27,000
| Closed | -$513K |
|
73
Trupanion
TRUP
$1.9B
| – | – |
-192,099
| Closed | -$7.2M |
|
74
UnitedHealth
UNH
$279B
| – | – |
-692
| Closed | -$203K |
|
75
Viatris
VTRS
$12.3B
| – | – |
-532,783
| Closed | -$10.7M |
|